Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

  • Technology appraisal guidance
  • TA38
  • Published: 
Download guidance (PDF)

9 Sources of evidence

The following documentation and opinion was made available to the appraisals committee.

a. Assessment report prepared by School of Health Related Research (ScHARR), University of Sheffield, (Clinical and Cost Effectiveness of Inhaler Devices used in the Routine Management of Chronic Asthma in Older Children, August 2001).

b. Manufacturer/sponsor submissions:

  • 3M Health Care Ltd

  • AstraZeneca UK Ltd

  • Aventis Pharma Ltd

  • Boehringer Ingelheim

  • Celltech Pharmaceuticals Ltd

  • GlaxoSmithKline

  • Norton Healthcare

  • Trinity Pharmaceuticals

  • Yamanouchi Pharma Ltd

c. Professional/specialist group, patient/carer group and trade association submissions:

  • British Lung Foundation

  • Royal College of Paediatrics and Child Health

  • The General Practice Airways Group (GPIAG)

  • British Thoracic Society

  • National Asthma Campaign

d. External expert and patient advocate attendance:

  • Dr Mark Levy, Representative from GPIAG and Senior Lecturer (Clinical) Part Time, Dept of General Practice & Primary Care, Aberdeen University

  • Trisha Weller, Head of Quality Assurance, National Asthma & Respiratory Training Centre

  • Dr Mark Everard, Consultant in Paediatric Respiratory Medicine, Sheffield Children's Hospital

  • Marsha Williams, Campaigns Manager, National Asthma Campaign

  • Jack Barnes, Director of Research & Policy, National Asthma Campaign

  • Dr Andrew Bush, on behalf of the British Lung Foundation, Reader in Paediatric Respirology, Royal Brompton Hospital

ISBN: 978-1-4731-5681-4